<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-148946" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Biochemistry, Very Low Density Lipoprotein</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Juarez Casso</surname>
            <given-names>Fernando M.</given-names>
          </name>
          <aff>Mayo Clinic</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Farzam</surname>
            <given-names>Khashayar</given-names>
          </name>
          <aff>McMaster University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Fernando Juarez Casso declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Khashayar Farzam declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>4</day>
          <month>12</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-148946.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Very low-density lipoproteins (VLDL), along with chylomicrons, low-density lipoproteins (LDL), intermediate-density lipoproteins (IDL), and high-density lipoproteins (HDL) are the&#x000a0;5 major types of lipoproteins. These lipoproteins transport hydrophobic lipids such as phospholipids, triglycerides, and cholesterol in the plasma and extracellular fluids. Lipids, proteins, carbohydrates, and nucleic acids are the main components of cellular life. Lipids are vital for synthesizing cell membranes, energy storage, intracellular messaging, and transporting other essential organic substances such as vitamins. Lipoproteins allow for the transport of hydrophobic lipids in the hydrophilic environment of the body&#x02019;s systemic circulation.<xref ref-type="bibr" rid="article-148946.r1">[1]</xref></p>
        <p>The synthesis and secretion of VLDL into circulation by the liver is a highly complex and regulated process that plays a fundamental role in the overall homeostasis of lipids in the body. Recent evidence has shown that the enhanced production and secretion of VLDL or alterations in its regulatory system directly contribute to developing multiorgan diseases such as atherosclerosis.<xref ref-type="bibr" rid="article-148946.r2">[2]</xref><xref ref-type="bibr" rid="article-148946.r3">[3]</xref><xref ref-type="bibr" rid="article-148946.r4">[4]</xref>&#x000a0;There is an ongoing research effort to understand better the basic and complicated mechanisms behind the regulation and signaling of VLDL biogenesis to develop effective targeted therapies in the future.</p>
      </sec>
      <sec id="article-148946.s2" sec-type="Fundamentals">
        <title>Fundamentals</title>
        <p>The composition of VLDL consists of approximately 90% lipids and 10% proteins. This proportion gives VLDL a low density of 0.96 to 1.006 g/ml, hence its name. Of its total lipid component, triglycerides take up to 70% of VLDL&#x02019;s mass, with cholesterol esters and fatty acids making up the rest.<xref ref-type="bibr" rid="article-148946.r5">[5]</xref>&#x000a0;Regarding its lower protein component, VLDL is associated with multiple apolipoproteins: Apo B-100, Apo C-I, Apo C-II, Apo C-III, and Apo E.<xref ref-type="bibr" rid="article-148946.r6">[6]</xref>&#x000a0;Apolipoproteins are cofactors for numerous enzymes throughout the body, ligands for surface receptors, and essential structural elements. The biological functions and metabolism of VLDL are strongly related to these apolipoproteins, as well as VLDL&#x02019;s potential role in disease development.<xref ref-type="bibr" rid="article-148946.r6">[6]</xref></p>
      </sec>
      <sec id="article-148946.s3" sec-type="Molecular Level&#x0000d;&#x0000a;">
        <title>Molecular Level
</title>
        <p>The lipid transport pathway starts in the small intestine when the dietary lipids (mainly triglycerides) are packaged into chylomicrons utilizing Apo B-48 as its backbone structure. Chylomicrons are then secreted into the lymphatic system to later travel throughout the systemic circulation. As they travel throughout the body, chylomicrons obtain Apo C-II and Apo-E from circulating HDL. The recently acquired Apo C-II acts as an activating cofactor for lipoprotein lipase (LPL), which hydrolyzes the triglycerides found in the chylomicrons&#x02019; core and allows it to release free fatty acids to the peripheral tissues. As chylomicrons lose their triglycerides by the action of peripheral LPL, they transform into chylomicron remnants. These remnants use their Apo-E as high-affinity ligands to bind to hepatic receptors and internalize into the liver.<xref ref-type="bibr" rid="article-148946.r1">[1]</xref>&#x000a0;</p>
        <p>In the hepatocytes, triglycerides and cholesterol esters are transferred to Apo B-100 by the action of the microsomal triglyceride transfer protein (MTTP). This lipidated Apo B-100 is now called nascent VLDL and is secreted to the circulation.<xref ref-type="bibr" rid="article-148946.r7">[7]</xref><xref ref-type="bibr" rid="article-148946.r8">[8]</xref>&#x000a0;Like chylomicrons, Nascent VLDL obtains Apo C-II and Apo-E from circulating HDL and is now termed mature VLDL. Mature VLDL transports endogenous lipids from the liver to the peripheral adipose, cardiac, and muscle tissues (unlike chylomicrons, which carry exogenous dietary lipids from the small intestine).<xref ref-type="bibr" rid="article-148946.r9">[9]</xref></p>
        <p>The Apo C-II in mature VLDL activates LPL in the capillary endothelium of tissues to cleave their stored triglycerides into&#x000a0;1 monoglyceride and&#x000a0;2 free fatty acids, releasing them from the VLDL and allowing them to be delivered to the tissues to be used for storage or energy production.<xref ref-type="bibr" rid="article-148946.r9">[9]</xref><xref ref-type="bibr" rid="article-148946.r10">[10]</xref>&#x000a0;Insulin also upregulates Apo C-II's activity and increases triglyceride hydrolysis into free fatty acids for tissue absorption. Simultaneously, the cholesterol ester transfer protein (CETP) promotes the exchange of VLDL&#x02019;s triglycerides and phospholipids for HDL&#x02019;s cholesterol esters. After releasing enough triglycerides either into the tissues or to HDL, the core of the VLDL gets reduced, and the VLDL remnant is now called IDL.&#x000a0;Approximately half of the circulating IDL is then taken by the liver by binding to the Apo B-100 and Apo-E. The remaining half of the IDL loses its Apo-E and transforms into LDL through the action of the hepatic lipase.&#x000a0;</p>
        <p>The alteration or deficiency of the enzymes involved in this complex metabolic process may lead to lipid disorders known as hyperlipoproteinemia. These diseases are divided into&#x000a0;5 subtypes depending on the pathophysiology and clinical presentation. Type I hyperlipoproteinemia (familial hyperchylomicronemia) is caused by a deficiency in LPL or Apo C-II, significantly increasing triglyceride concentration. These patients present with eruptive xanthomas, steatosis, recurrent episodes of acute pancreatitis, and no increased risk of atherosclerosis.<xref ref-type="bibr" rid="article-148946.r11">[11]</xref>&#x000a0;Defective or deficient LDL receptors or Apo B-100 causes type II hyperlipoproteinemia (familial hypercholesterolemia). This causes an important elevation in LDL (usually &#x0003e;600 mg/dl in homozygotes or &#x0003e;250 mg/dl in heterozygotes) and VLDL cholesterol. These patients present with tuberous xanthomas, xanthelasmas, and premature atherosclerosis, which may lead to acute coronary syndromes in young patients (&#x0003c;20 years of age).<xref ref-type="bibr" rid="article-148946.r12">[12]</xref>&#x000a0;Type III hyperlipoproteinemia (familial dysbetalipoproteinemia) is caused by an alteration in Apo-E, which increases VLDL and chylomicrons, leading to premature atherosclerosis.<xref ref-type="bibr" rid="article-148946.r13">[13]</xref>&#x000a0;Type IV hyperlipoproteinemia (familial hypertriglyceridemia) is caused by hepatic overproduction of VLDL, leading to a massive increase in triglyceride concentrations (usually &#x0003e;1000 mg/dl), causing premature atherosclerosis and recurrent episodes of acute pancreatitis (similar to type I).<xref ref-type="bibr" rid="article-148946.r14">[14]</xref><xref ref-type="bibr" rid="article-148946.r15">[15]</xref>&#x000a0;Finally, type V (mixed hyperlipidemia) is caused by a sporadic defect in Apo A5 and presents with xanthomas, abdominal pain, and clinical features of hyperglycemia.<xref ref-type="bibr" rid="article-148946.r16">[16]</xref><xref ref-type="bibr" rid="article-148946.r17">[17]</xref></p>
      </sec>
      <sec id="article-148946.s4" sec-type="Function">
        <title>Function</title>
        <p>LDL plays a key role in forming atherosclerotic plaques that lead to atherosclerotic cardiovascular disease. Directly measuring LDL and VLDL by ultracentrifugation is extremely expensive and time-consuming. For this reason, multiple time and money-saving equations have been developed to estimate the LDL and VLDL cholesterol levels. Most famously known, the Friedewald equation subtracts HDL and VLDL from the total cholesterol level to estimate LDL concentration. In turn, VLDL levels are estimated by a fixed ratio of triglycerides/5.<xref ref-type="bibr" rid="article-148946.r18">[18]</xref>&#x000a0;</p>
        <p>Initially intended for research purposes only, this equation has been widely utilized over the last decades to estimate LDL cholesterol levels clinically.<xref ref-type="bibr" rid="article-148946.r19">[19]</xref>&#x000a0;This equation, however, is not without its limitations and inaccuracies. This measurement becomes unreliable at high triglyceride (&#x0003e;400 mg/dl) and low LDL concentrations.&#x000a0;With the increased prevalence of obesity, metabolic syndrome, and diabetes, higher triglyceride levels are increasingly common, and special consideration needs to be taken when indirectly estimating both LDL and VLDL.<xref ref-type="bibr" rid="article-148946.r20">[20]</xref></p>
      </sec>
      <sec id="article-148946.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Diet, sex, and race are factors that significantly influence VLDL production and secretion. VLDL synthesis is mainly related to lipid intake, with secretion increasing in the postprandial state. High-fat diets have been associated with higher VLDL secretion, usually presenting as increased blood triglyceride levels.<xref ref-type="bibr" rid="article-148946.r21">[21]</xref><xref ref-type="bibr" rid="article-148946.r22">[22]</xref> Studies have inconsistently reported the timing of postprandial VLDL peaks, ranging from 30 minutes up to 5 or 6 hours. Nonetheless, multiple studies have found that insulin resistance, metabolic syndrome, and obesity are strongly associated with longer plateaus and higher peaks of VLDL levels.<xref ref-type="bibr" rid="article-148946.r23">[23]</xref><xref ref-type="bibr" rid="article-148946.r24">[24]</xref>&#x000a0;Women have also been shown to have lower VLDL concentrations than men, although the cause of this sex difference is not completely understood.<xref ref-type="bibr" rid="article-148946.r25">[25]</xref>&#x000a0;VLDL has been associated with the development of multiple pathological conditions involving the cardiovascular, endocrine, renal, hepatic, and nervous systems, as well as cancer and several autoimmune and dermatological diseases.</p>
      </sec>
      <sec id="article-148946.s6" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>The impact of VLDL on cardiovascular diseases is mainly correlated to its role in atherosclerosis and coronary disease.<xref ref-type="bibr" rid="article-148946.r26">[26]</xref>&#x000a0;The accumulation of triglyceride-predominant lipoproteins such as chylomicrons and VLDL strongly contributes to the rupture of atherosclerotic plaques. Additionally, VLDL has been associated with peripheral artery disease, leading to occlusive limb events, vascular stiffness, and carotid artery thickness.<xref ref-type="bibr" rid="article-148946.r27">[27]</xref>&#x000a0;Besides the lipidic components of VLDL, its apolipoprotein composition also directly affects the development of cardiovascular disorders. Studies have shown that higher Apo-B and lower Apo C-III concentrations are associated with higher cardiovascular risk.<xref ref-type="bibr" rid="article-148946.r28">[28]</xref><xref ref-type="bibr" rid="article-148946.r29">[29]</xref>&#x000a0;This leads to the hypothesis that Apo-B is one of the major drivers in the development of atherosclerosis.<xref ref-type="bibr" rid="article-148946.r30">[30]</xref></p>
        <p>Beyond its direct relation with atherosclerosis, VLDL also plays an important role in metabolic syndrome and insulin resistance. In a normal physiologic state, insulin suppresses the production and secretion of VLDL. In subjects with insulin resistance, an enhanced synthesis and reduced clearance of VLDL is often detected as increased plasma triglyceride levels.<xref ref-type="bibr" rid="article-148946.r31">[31]</xref><xref ref-type="bibr" rid="article-148946.r32">[32]</xref>&#x000a0;In these subjects with insulin resistance, there is also a dysfunction in lipid storage in adipose tissue, making them prone to hyperlipidemia. Further, VLDL in metabolic syndrome can induce macrophage apoptosis by increasing reactive oxygen species production. These cytotoxic properties cause VLDL to be highly pro-inflammatory and atherogenic.<xref ref-type="bibr" rid="article-148946.r29">[29]</xref></p>
        <p>VLDL cholesterol is also associated with hepatic disorders such as non-alcoholic fatty liver disease (NAFLD) and hepatitis. Liver fat content has been previously associated with other features of chronic insulin resistance, such as glucose intolerance, increased insulin levels, and intra-abdominal fat.<xref ref-type="bibr" rid="article-148946.r2">[2]</xref>&#x000a0;In subjects with NAFLD, there is increased hydrolysis of intrahepatic triglycerides, leading to increased secretion of VLDL. Patients with NAFLD also have an altered synthesis, oxidation, and reduction of VLDL particles due to the impaired effects of insulin.<xref ref-type="bibr" rid="article-148946.r31">[31]</xref>&#x000a0;It has been theorized that the lessened effects of insulin lead to an increase in lipid deposition from adipose tissue to the liver. Elevations in blood glucose can further increase fat accumulation in the liver, resulting in enhanced production of VLDL and leading to the expected hyperlipidemia associated with diabetes.<xref ref-type="bibr" rid="article-148946.r2">[2]</xref></p>
        <p>Various hormones also affect VLDL levels, with their metabolism closely related to several endocrinological mechanisms. In Cushing syndrome, the increased concentration of cortisol increases the plasma levels of both VLDL and LDL cholesterol&#x000a0;by reducing the degradation of Apo B and increasing the rate of adipose tissue lipolysis.<xref ref-type="bibr" rid="article-148946.r33">[33]</xref>&#x000a0;This&#x000a0;results in expected dyslipidemia and increased cardiovascular risk associated with Cushing syndrome. VLDL stimulates aldosterone production and potentially leads to hypertension. This also explains how statins are associated with a decrease in aldosterone concentrations.<xref ref-type="bibr" rid="article-148946.r34">[34]</xref>&#x000a0;Growth hormone also has a direct effect on VLDL metabolism.<xref ref-type="bibr" rid="article-148946.r35">[35]</xref>&#x000a0;Growth hormone deficiency is associated with increased VLDL synthesis and decreased clearance. This mechanism explains the association between hypopituitarism and a higher cardiovascular and cerebrovascular risk.&#x000a0;Moreover, thyroid hormones affect the activity of LPL and strongly relate to cholesterol metabolism. The deficiency of thyroid hormones in hypothyroidism leads to reduced LPL function and increased hepatic VLDL production associated with hyperlipidemia and higher cardiovascular risk.<xref ref-type="bibr" rid="article-148946.r36">[36]</xref>&#x000a0;VLDL has also been implicated in developing neurocognitive dysfunction, chronic kidney disease, and cancer.<xref ref-type="bibr" rid="article-148946.r37">[37]</xref><xref ref-type="bibr" rid="article-148946.r38">[38]</xref><xref ref-type="bibr" rid="article-148946.r39">[39]</xref></p>
        <p>In conclusion,&#x000a0;VLDL cholesterol is synthesized in the liver to transport endogenous lipids such as triglycerides and cholesterol esters to the peripheral (mainly adipose, skeletal, and cardiac) tissues. It has been strongly associated with developing several multiorgan diseases such as atherosclerosis, coronary artery disease, non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome, neurocognitive impairment, autoimmune disease, dermatological disorders, and cancer. It is crucial to study and understand the mechanisms behind VLDL&#x02019;s biosynthesis, regulation, signaling, and secretion to comprehend its contribution to human health and to potentially develop targeted therapies that may lead directly to better patient care.</p>
      </sec>
      <sec id="article-148946.s7">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=148946&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=148946">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/148946/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=148946">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-148946.s8">
        <title>References</title>
        <ref id="article-148946.r1">
          <label>1</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Lent-Schochet</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Jialal</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <chapter-title>Biochemistry, Lipoprotein Metabolism</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>1</month>
            <day>16</day>
            <pub-id pub-id-type="pmid">31985986</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148946.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Adiels</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Taskinen</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Packard</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Caslake</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Soro-Paavonen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Westerbacka</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vehkavaara</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>H&#x000e4;kkinen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Olofsson</surname>
                <given-names>SO</given-names>
              </name>
              <name>
                <surname>Yki-J&#x000e4;rvinen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bor&#x000e9;n</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Overproduction of large VLDL particles is driven by increased liver fat content in man.</article-title>
            <source>Diabetologia</source>
            <year>2006</year>
            <month>Apr</month>
            <volume>49</volume>
            <issue>4</issue>
            <fpage>755</fpage>
            <page-range>755-65</page-range>
            <pub-id pub-id-type="pmid">16463046</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148946.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Johansen</surname>
                <given-names>M&#x000d8;</given-names>
              </name>
              <name>
                <surname>Nielsen</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Afzal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vedel-Krogh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Davey Smith</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Nordestgaard</surname>
                <given-names>BG</given-names>
              </name>
            </person-group>
            <article-title>Very Low-Density Lipoprotein Cholesterol May Mediate a Substantial Component of the Effect of Obesity on Myocardial Infarction Risk: The Copenhagen General Population Study.</article-title>
            <source>Clin Chem</source>
            <year>2021</year>
            <month>Jan</month>
            <day>08</day>
            <volume>67</volume>
            <issue>1</issue>
            <fpage>276</fpage>
            <page-range>276-287</page-range>
            <pub-id pub-id-type="pmid">33409531</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148946.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Balling</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Afzal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Varbo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Langsted</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Davey Smith</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Nordestgaard</surname>
                <given-names>BG</given-names>
              </name>
            </person-group>
            <article-title>VLDL Cholesterol Accounts for One-Half of the Risk of Myocardial Infarction Associated With apoB-Containing Lipoproteins.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2020</year>
            <month>Dec</month>
            <day>08</day>
            <volume>76</volume>
            <issue>23</issue>
            <fpage>2725</fpage>
            <page-range>2725-2735</page-range>
            <pub-id pub-id-type="pmid">33272366</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148946.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dashti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kulik</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Hoek</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Veerman</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Peppelenbosch</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Rezaee</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>A phospholipidomic analysis of all defined human plasma lipoproteins.</article-title>
            <source>Sci Rep</source>
            <year>2011</year>
            <volume>1</volume>
            <fpage>139</fpage>
            <pub-id pub-id-type="pmid">22355656</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148946.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dashty</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Motazacker</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Levels</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>de Vries</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mahmoudi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Peppelenbosch</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Rezaee</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Proteome of human plasma very low-density lipoprotein and low-density lipoprotein exhibits a link with coagulation and lipid metabolism.</article-title>
            <source>Thromb Haemost</source>
            <year>2014</year>
            <month>Mar</month>
            <day>03</day>
            <volume>111</volume>
            <issue>3</issue>
            <fpage>518</fpage>
            <page-range>518-30</page-range>
            <pub-id pub-id-type="pmid">24500811</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148946.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gibbons</surname>
                <given-names>GF</given-names>
              </name>
              <name>
                <surname>Wiggins</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Hebbachi</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Synthesis and function of hepatic very-low-density lipoprotein.</article-title>
            <source>Biochem Soc Trans</source>
            <year>2004</year>
            <month>Feb</month>
            <volume>32</volume>
            <issue>Pt 1</issue>
            <fpage>59</fpage>
            <page-range>59-64</page-range>
            <pub-id pub-id-type="pmid">14748713</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148946.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tiwari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Siddiqi</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Intracellular trafficking and secretion of VLDL.</article-title>
            <source>Arterioscler Thromb Vasc Biol</source>
            <year>2012</year>
            <month>May</month>
            <volume>32</volume>
            <issue>5</issue>
            <fpage>1079</fpage>
            <page-range>1079-86</page-range>
            <pub-id pub-id-type="pmid">22517366</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148946.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nimpf</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schneider</surname>
                <given-names>WJ</given-names>
              </name>
            </person-group>
            <article-title>From cholesterol transport to signal transduction: low density lipoprotein receptor, very low density lipoprotein receptor, and apolipoprotein E receptor-2.</article-title>
            <source>Biochim Biophys Acta</source>
            <year>2000</year>
            <month>Dec</month>
            <day>15</day>
            <volume>1529</volume>
            <issue>1-3</issue>
            <fpage>287</fpage>
            <page-range>287-98</page-range>
            <pub-id pub-id-type="pmid">11111096</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148946.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shelness</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Sellers</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Very-low-density lipoprotein assembly and secretion.</article-title>
            <source>Curr Opin Lipidol</source>
            <year>2001</year>
            <month>Apr</month>
            <volume>12</volume>
            <issue>2</issue>
            <fpage>151</fpage>
            <page-range>151-7</page-range>
            <pub-id pub-id-type="pmid">11264986</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148946.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Teramoto</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tada</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kawashiri</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Nohara</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nakahashi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Konno</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Inazu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mabuchi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yamagishi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hayashi</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Molecular and functional characterization of familial chylomicronemia syndrome.</article-title>
            <source>Atherosclerosis</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>269</volume>
            <fpage>272</fpage>
            <page-range>272-278</page-range>
            <pub-id pub-id-type="pmid">29153744</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148946.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abifadel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Boileau</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Genetic and molecular architecture of familial hypercholesterolemia.</article-title>
            <source>J Intern Med</source>
            <year>2023</year>
            <month>Feb</month>
            <volume>293</volume>
            <issue>2</issue>
            <fpage>144</fpage>
            <page-range>144-165</page-range>
            <pub-id pub-id-type="pmid">36196022</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148946.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sampson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wolska</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Meeusen</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Donato</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Jaffe</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Remaley</surname>
                <given-names>AT</given-names>
              </name>
            </person-group>
            <article-title>Identification of Dysbetalipoproteinemia by an Enhanced Sampson-NIH Equation for Very Low-Density Lipoprotein-Cholesterol.</article-title>
            <source>Front Genet</source>
            <year>2022</year>
            <volume>13</volume>
            <fpage>935257</fpage>
            <pub-id pub-id-type="pmid">35910208</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148946.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rodrigues</surname>
                <given-names>KF</given-names>
              </name>
              <name>
                <surname>Yong</surname>
                <given-names>WTL</given-names>
              </name>
              <name>
                <surname>Bhuiyan</surname>
                <given-names>MSA</given-names>
              </name>
              <name>
                <surname>Siddiquee</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Venmathi Maran</surname>
                <given-names>BA</given-names>
              </name>
            </person-group>
            <article-title>Current Understanding on the Genetic Basis of Key Metabolic Disorders: A Review.</article-title>
            <source>Biology (Basel)</source>
            <year>2022</year>
            <month>Sep</month>
            <day>02</day>
            <volume>11</volume>
            <issue>9</issue>
            <pub-id pub-id-type="pmid">36138787</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148946.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grundy</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome.</article-title>
            <source>Am J Cardiol</source>
            <year>1998</year>
            <month>Feb</month>
            <day>26</day>
            <volume>81</volume>
            <issue>4A</issue>
            <fpage>18B</fpage>
            <page-range>18B-25B</page-range>
            <pub-id pub-id-type="pmid">9526809</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148946.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ban</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Kennedy</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Anand</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yusuf</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Huff</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Pollex</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Hegele</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>APOA5 genetic variants are markers for classic hyperlipoproteinemia phenotypes and hypertriglyceridemia.</article-title>
            <source>Nat Clin Pract Cardiovasc Med</source>
            <year>2008</year>
            <month>Nov</month>
            <volume>5</volume>
            <issue>11</issue>
            <fpage>730</fpage>
            <page-range>730-7</page-range>
            <pub-id pub-id-type="pmid">18779834</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148946.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fallat</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Glueck</surname>
                <given-names>CJ</given-names>
              </name>
            </person-group>
            <article-title>Familial and acquired type V hyperlipoproteinemia.</article-title>
            <source>Atherosclerosis</source>
            <year>1976</year>
            <season>Jan-Feb</season>
            <volume>23</volume>
            <issue>1</issue>
            <fpage>41</fpage>
            <page-range>41-62</page-range>
            <pub-id pub-id-type="pmid">1078394</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148946.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Friedewald</surname>
                <given-names>WT</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>RI</given-names>
              </name>
              <name>
                <surname>Fredrickson</surname>
                <given-names>DS</given-names>
              </name>
            </person-group>
            <article-title>Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.</article-title>
            <source>Clin Chem</source>
            <year>1972</year>
            <month>Jun</month>
            <volume>18</volume>
            <issue>6</issue>
            <fpage>499</fpage>
            <page-range>499-502</page-range>
            <pub-id pub-id-type="pmid">4337382</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148946.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Warnick</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Knopp</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Fitzpatrick</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Branson</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Estimating low-density lipoprotein cholesterol by the Friedewald equation is adequate for classifying patients on the basis of nationally recommended cutpoints.</article-title>
            <source>Clin Chem</source>
            <year>1990</year>
            <month>Jan</month>
            <volume>36</volume>
            <issue>1</issue>
            <fpage>15</fpage>
            <page-range>15-9</page-range>
            <pub-id pub-id-type="pmid">2297909</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148946.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martin</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Blaha</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Elshazly</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Brinton</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Toth</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>McEvoy</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Joshi</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Kulkarni</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Mize</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Kwiterovich</surname>
                <given-names>PO</given-names>
              </name>
              <name>
                <surname>Defilippis</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Blumenthal</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>Friedewald-estimated versus directly measured low-density lipoprotein cholesterol and treatment implications.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2013</year>
            <month>Aug</month>
            <day>20</day>
            <volume>62</volume>
            <issue>8</issue>
            <fpage>732</fpage>
            <page-range>732-9</page-range>
            <pub-id pub-id-type="pmid">23524048</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148946.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lambert</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Parks</surname>
                <given-names>EJ</given-names>
              </name>
            </person-group>
            <article-title>Postprandial metabolism of meal triglyceride in humans.</article-title>
            <source>Biochim Biophys Acta</source>
            <year>2012</year>
            <month>May</month>
            <volume>1821</volume>
            <issue>5</issue>
            <fpage>721</fpage>
            <page-range>721-6</page-range>
            <pub-id pub-id-type="pmid">22281699</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148946.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nakajima</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nakano</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tokita</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Nagamine</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Inazu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kobayashi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mabuchi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Stanhope</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Havel</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Okazaki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ai</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Postprandial lipoprotein metabolism: VLDL vs chylomicrons.</article-title>
            <source>Clin Chim Acta</source>
            <year>2011</year>
            <month>Jul</month>
            <day>15</day>
            <volume>412</volume>
            <issue>15-16</issue>
            <fpage>1306</fpage>
            <page-range>1306-18</page-range>
            <pub-id pub-id-type="pmid">21531214</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148946.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>S&#x000f8;ndergaard</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Johansen</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Nielsen</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Postprandial VLDL-TG metabolism in type 2 diabetes.</article-title>
            <source>Metabolism</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>75</volume>
            <fpage>25</fpage>
            <page-range>25-35</page-range>
            <pub-id pub-id-type="pmid">28964326</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148946.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Shin</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>YH</given-names>
              </name>
              <name>
                <surname>Ke</surname>
                <given-names>LY</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Tsai</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Chao</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>YH</given-names>
              </name>
            </person-group>
            <article-title>The role of postprandial very-low-density lipoprotein in the development of atrial remodeling in metabolic syndrome.</article-title>
            <source>Lipids Health Dis</source>
            <year>2020</year>
            <month>Sep</month>
            <day>22</day>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>210</fpage>
            <pub-id pub-id-type="pmid">32962696</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148946.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gormsen</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>H&#x000f8;st</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hjerrild</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Gravholt</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Nielsen</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Acute estrogen exposure does not affect basal very low-density lipoprotein-triglyceride production or oxidation in postmenopausal women.</article-title>
            <source>Eur J Endocrinol</source>
            <year>2010</year>
            <month>Sep</month>
            <volume>163</volume>
            <issue>3</issue>
            <fpage>421</fpage>
            <page-range>421-6</page-range>
            <pub-id pub-id-type="pmid">20566588</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148946.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sacks</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Alaupovic</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Moye</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Cole</surname>
                <given-names>TG</given-names>
              </name>
              <name>
                <surname>Sussex</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Stampfer</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Pfeffer</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Braunwald</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial.</article-title>
            <source>Circulation</source>
            <year>2000</year>
            <month>Oct</month>
            <day>17</day>
            <volume>102</volume>
            <issue>16</issue>
            <fpage>1886</fpage>
            <page-range>1886-92</page-range>
            <pub-id pub-id-type="pmid">11034934</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148946.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gentile</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Iannuzzi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Giallauria</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>D'Andrea</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Venturini</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pacileo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Covetti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Panico</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mattiello</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vitale</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sarullo</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Rubba</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Vigorito</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Panico</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Iannuzzo</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Association between Very Low-Density Lipoprotein Cholesterol (VLDL-C) and Carotid Intima-Media Thickness in Postmenopausal Women Without Overt Cardiovascular Disease and on LDL-C Target Levels.</article-title>
            <source>J Clin Med</source>
            <year>2020</year>
            <month>May</month>
            <day>11</day>
            <volume>9</volume>
            <issue>5</issue>
            <pub-id pub-id-type="pmid">32403373</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148946.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ginsberg</surname>
                <given-names>HN</given-names>
              </name>
              <name>
                <surname>Packard</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Chapman</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Bor&#x000e9;n</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Aguilar-Salinas</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Averna</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ference</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Gaudet</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hegele</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Kersten</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>GF</given-names>
              </name>
              <name>
                <surname>Lichtenstein</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Moulin</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Nordestgaard</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Remaley</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Staels</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Stroes</surname>
                <given-names>ESG</given-names>
              </name>
              <name>
                <surname>Taskinen</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Tokg&#x000f6;zo&#x0011f;lu</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Tybjaerg-Hansen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Stock</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Catapano</surname>
                <given-names>AL</given-names>
              </name>
            </person-group>
            <article-title>Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society.</article-title>
            <source>Eur Heart J</source>
            <year>2021</year>
            <month>Dec</month>
            <day>14</day>
            <volume>42</volume>
            <issue>47</issue>
            <fpage>4791</fpage>
            <page-range>4791-4806</page-range>
            <pub-id pub-id-type="pmid">34472586</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148946.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mendivil</surname>
                <given-names>CO</given-names>
              </name>
              <name>
                <surname>Rimm</surname>
                <given-names>EB</given-names>
              </name>
              <name>
                <surname>Furtado</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sacks</surname>
                <given-names>FM</given-names>
              </name>
            </person-group>
            <article-title>Apolipoprotein E in VLDL and LDL with apolipoprotein C-III is associated with a lower risk of coronary heart disease.</article-title>
            <source>J Am Heart Assoc</source>
            <year>2013</year>
            <month>May</month>
            <day>14</day>
            <volume>2</volume>
            <issue>3</issue>
            <fpage>e000130</fpage>
            <pub-id pub-id-type="pmid">23672999</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148946.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marston</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Giugliano</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Melloni</surname>
                <given-names>GEM</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Morrill</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Blazing</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Ference</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Stroes</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Braunwald</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ellinor</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Lubitz</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Ruff</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Sabatine</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>Association of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis: Distinguishing Between Particle Concentration, Type, and Content.</article-title>
            <source>JAMA Cardiol</source>
            <year>2022</year>
            <month>Mar</month>
            <day>01</day>
            <volume>7</volume>
            <issue>3</issue>
            <fpage>250</fpage>
            <page-range>250-256</page-range>
            <pub-id pub-id-type="pmid">34773460</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148946.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Poulsen</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Nellemann</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>St&#x000f8;dkilde-J&#x000f8;rgensen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Pedersen</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Gr&#x000f8;nb&#x000e6;k</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Nielsen</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Impaired Insulin Suppression of VLDL-Triglyceride Kinetics in Nonalcoholic Fatty Liver Disease.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>101</volume>
            <issue>4</issue>
            <fpage>1637</fpage>
            <page-range>1637-46</page-range>
            <pub-id pub-id-type="pmid">26829441</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148946.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tric&#x000f2;</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Natali</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mari</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ferrannini</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Santoro</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Caprio</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Triglyceride-rich very low-density lipoproteins (VLDL) are independently associated with insulin secretion in a multiethnic cohort of adolescents.</article-title>
            <source>Diabetes Obes Metab</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>20</volume>
            <issue>12</issue>
            <fpage>2905</fpage>
            <page-range>2905-2910</page-range>
            <pub-id pub-id-type="pmid">30003666</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148946.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Giordano</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Picu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Marinazzo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>D'Angelo</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Berardelli</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Karamouzis</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Forno</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zinn&#x000e0;</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Maccario</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ghigo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Arvat</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Metabolic and cardiovascular outcomes in patients with Cushing's syndrome of different aetiologies during active disease and 1 year after remission.</article-title>
            <source>Clin Endocrinol (Oxf)</source>
            <year>2011</year>
            <month>Sep</month>
            <volume>75</volume>
            <issue>3</issue>
            <fpage>354</fpage>
            <page-range>354-60</page-range>
            <pub-id pub-id-type="pmid">21521323</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148946.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baudrand</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pojoga</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Vaidya</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Garza</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>V&#x000f6;hringer</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Jeunemaitre</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Hopkins</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>Yao</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Adler</surname>
                <given-names>GK</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>GH</given-names>
              </name>
            </person-group>
            <article-title>Statin Use and Adrenal Aldosterone Production in Hypertensive and Diabetic Subjects.</article-title>
            <source>Circulation</source>
            <year>2015</year>
            <month>Nov</month>
            <day>10</day>
            <volume>132</volume>
            <issue>19</issue>
            <fpage>1825</fpage>
            <page-range>1825-33</page-range>
            <pub-id pub-id-type="pmid">26432671</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148946.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>M&#x000f8;ller</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>J&#x000f8;rgensen</surname>
                <given-names>JO</given-names>
              </name>
            </person-group>
            <article-title>Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects.</article-title>
            <source>Endocr Rev</source>
            <year>2009</year>
            <month>Apr</month>
            <volume>30</volume>
            <issue>2</issue>
            <fpage>152</fpage>
            <page-range>152-77</page-range>
            <pub-id pub-id-type="pmid">19240267</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148946.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fabbrini</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Magkos</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Patterson</surname>
                <given-names>BW</given-names>
              </name>
              <name>
                <surname>Mittendorfer</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Subclinical hypothyroidism and hyperthyroidism have opposite effects on hepatic very-low-density lipoprotein-triglyceride kinetics.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2012</year>
            <month>Mar</month>
            <volume>97</volume>
            <issue>3</issue>
            <fpage>E414</fpage>
            <page-range>E414-8</page-range>
            <pub-id pub-id-type="pmid">22238397</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148946.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yogi-Morren</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Galioto</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Strandjord</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Kennedy</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Manroa</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kirwan</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Kashyap</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gunstad</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Duration of type 2 diabetes and very low density lipoprotein levels are associated with cognitive dysfunction in metabolic syndrome.</article-title>
            <source>Cardiovasc Psychiatry Neurol</source>
            <year>2014</year>
            <volume>2014</volume>
            <fpage>656341</fpage>
            <pub-id pub-id-type="pmid">25057411</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148946.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miljkovic</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stefanovic</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Simic-Ogrizovic</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Vekic</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bogavac-Stanojevic</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Cerne</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kocbek</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Marc</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Jelic-Ivanovic</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Spasojevic-Kalimanovska</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Kotur-Stevuljevic</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Association of Dyslipidemia, Oxidative Stress, and Inflammation With Redox Status in VLDL, LDL, and HDL Lipoproteins in Patients With Renal Disease.</article-title>
            <source>Angiology</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>69</volume>
            <issue>10</issue>
            <fpage>861</fpage>
            <page-range>861-870</page-range>
            <pub-id pub-id-type="pmid">29909653</pub-id>
          </element-citation>
        </ref>
        <ref id="article-148946.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Butler</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Perone</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Dehairs</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lupien</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>de Laat</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Talebi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Loda</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kinlaw</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Swinnen</surname>
                <given-names>JV</given-names>
              </name>
            </person-group>
            <article-title>Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention.</article-title>
            <source>Adv Drug Deliv Rev</source>
            <year>2020</year>
            <volume>159</volume>
            <fpage>245</fpage>
            <page-range>245-293</page-range>
            <pub-id pub-id-type="pmid">32711004</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
